- Home
- DGII vs AUPH Comparison
DGII vs AUPH Comparison
Compare DGII & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- AUPH
- Stock Information
- Founded
- DGII 1985
- AUPH 1993
- Country
- DGII United States
- AUPH Canada
- Employees
- DGII N/A
- AUPH N/A
- Industry
- DGII Computer peripheral equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- AUPH Health Care
- Exchange
- DGII Nasdaq
- AUPH Nasdaq
- Market Cap
- DGII 1.3B
- AUPH 1.1B
- IPO Year
- DGII N/A
- AUPH 1999
- Fundamental
- Price
- DGII $34.10
- AUPH $8.86
- Analyst Decision
- DGII Hold
- AUPH Strong Buy
- Analyst Count
- DGII 4
- AUPH 2
- Target Price
- DGII $33.50
- AUPH $11.50
- AVG Volume (30 Days)
- DGII 149.4K
- AUPH 2.0M
- Earning Date
- DGII 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- DGII N/A
- AUPH N/A
- EPS Growth
- DGII 196.64
- AUPH N/A
- EPS
- DGII 1.13
- AUPH 0.27
- Revenue
- DGII $418,624,000.00
- AUPH $247,295,000.00
- Revenue This Year
- DGII $1.81
- AUPH $12.15
- Revenue Next Year
- DGII $4.34
- AUPH $18.31
- P/E Ratio
- DGII $29.89
- AUPH $33.08
- Revenue Growth
- DGII N/A
- AUPH 29.20
- 52 Week Low
- DGII $20.17
- AUPH $5.20
- 52 Week High
- DGII $37.07
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- DGII 49.23
- AUPH 64.10
- Support Level
- DGII $34.72
- AUPH $7.36
- Resistance Level
- DGII $35.57
- AUPH $9.10
- Average True Range (ATR)
- DGII 0.86
- AUPH 0.44
- MACD
- DGII -0.13
- AUPH 0.10
- Stochastic Oscillator
- DGII 39.28
- AUPH 89.53
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.